All News

knee.injx_.ant_.jpg

SPRINGBOARD: Extended-release Intra-articular Corticosteroid Injection in Knee OA

d Jack Cush, MD

A phase 2 trial of EP-104IAR (long-acting, fluticasone propionate) has shown 14 weeks of clinically meaningful pain relief in knee osteoarthritis (OA).

Read Article
vaccine.jpg

Inadequate Zoster Vaccination in Immunocompromised Patients

d Jack Cush, MD

A VA study of shows that recombinant zoster vaccine (RZV) vaccination in immunocompromised patients or those receiving immunosuppressive medications is insufficient, given these are high risk individuals.

Read Article
Trends in Early Undifferentiated PolyArthritis presentation. Over 3 eras (1998-2004-245 pts; 2005-10 266 pts; 2011-22 329 pts) many Sxs & Rx same. But Sxs duration 2.9 to 4.1mos, seropositivity 54 to 42%, Erosion score 18 to 9, mostly in Seroneg pts; Steroids incr 18 to 33%… https://t.co/AZfjqB4xGI https://t.co/GEwDWjccxl
Dr. John Cush RheumNow ( View Tweet)
Genentech announced top line results of the REGENCY Phase III study of obinutuzumab (Gazyva) in lupus nephritis. 271 LN (class III or IV; +/- V) taking MMF & steroids were given placebo or OBIN for 76 wks. OBIN was superior @ complete renal resp at 76 wks… https://t.co/Um9du7fgxE https://t.co/RRWumnbTuy
Dr. John Cush RheumNow ( View Tweet)
guidelines.jpg (keep)

British Society Guidelines for Managing Behçet’s Disease

d Jack Cush, MD

An exhaustive, full read guideline from the British Association of Dermatologists (BAD) and the British Society for Rheumatology (BSR) on the management and treatment of Behçet’s disease (BD) in 2024 has been published in Rheumatology.

Read Article
RheumNow Podcast square

I Can't Treat Ugly (9.20.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.

Read Article
lupus SLE

Mycophenolate in New-Onset SLE

d Jack Cush, MD

How aggressively do you treat newly diagnosed new-onset systemic lupus erythematosus (SLE), or should you wait for organ involvement?

Read Article
CV,risk,MI,heart,cardiac

Increased Cardiovascular Events in Lupus

d Jack Cush, MD

A New York surveillance registry (Manhattan Lupus Surveillance Program) estimates higher rates of cardiovascular events (CVE) among systemic lupus erythematosus (SLE) patients, especially amongst younger males, Hispanic/Latinos and non-Hispanic Black patients.

Read Article
1,717 Chinese rheumatologists (92% response) surveyed on Steroid use in RA. 60% admit to infrequent use of GC cotherapy. Bridging GC use was supported (35%), opposed (27%), but 38% were inconclusive & 67% said long-term low-dose GC use depends on the pt https://t.co/7qe1aRsZx8 https://t.co/D0RoYxPohY

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Systemic Sclerosis Insights (9.13.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article
Systematic literature review IVIG in systemic sclerosis included 12 studies, 266 pts. A favorable effect was seen for skin thickening, MSK pain, GI Sxs, Steroid use, QOL. But less effect for pulmonary Dz, PFTs (stabilized?). Studies were not of high-quality… https://t.co/c3Xix9K2XK https://t.co/L3LKwegmkf
Dr. John Cush RheumNow ( View Tweet)
Good Clinical Practice Recommendations on Glucocorticoid Withdrawal and Adrenal Insufficiency The European Society of Endocrinology and Endocrine Society have jointly published a clinical guideline on the diagnosis and treatment of glucocorticoid-induced adrenal insufficiency,… https://t.co/GmQ5ypvqWP https://t.co/oab9qHpxSa
Dr. John Cush RheumNow ( View Tweet)
urticaria

Urticarial Vasculitis Overview

d Jack Cush, MD

Urticarial vasculitis is rare and the causes often go undiagnosed. A Medscape recent overview highlights key features in the diagnosis and management of this rare disorder.

Read Article
steroid prednisone lab

Good Clinical Practice Recommendations on Glucocorticoid Withdrawal and Adrenal Insufficiency

d Jack Cush, MD

Glucocorticoids are widely prescribed as anti-inflammatory and immunosuppressive agents. This results in at least 1% of the population using chronic glucocorticoid therapy being at risk for glucocorticoid-induced adrenal insufficiency. This risk is dependent on the dose, duration and potency of the glucocorticoid, route of administration, and individual susceptibility.

Read Article
Retrospective observational study of 96 stable #SLE pts compared maintenance on HCQ vs belimumab. There were no significant differences in Flare rate (18% HCQ vs 8.3% BLM; p=0.47), damage index increase, SLEDAI, Pred dose or adverse events https://t.co/sVPMugSHn3 https://t.co/6bdel6Kvs9

Links:

Dr. John Cush RheumNow ( View Tweet)
It takes >3-4 weeks of steroids (@ any dose >5 mg pred/d) to pose risk of adrenal insufficiency – Hence, Endocrine Society Guideline says short-term glucocorticoid therapy of <3-4 wks, irrespective of dose, DOES NOT require GC tapering https://t.co/o7tz1Am9pe https://t.co/CndfCYRApj

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Running with Data (8.30.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com - including tips on steroids, MAS, and myositis testing.

Read Article
MDs: How long must you be on Pred 40 mg/d before you must slowly wean pred (vs stopping abruptly)?

Dr. John Cush RheumNow ( View Tweet)

Check out a NEW review on the dichotomy of #glucocorticosteroids treatment in #rheumaticdiseases by @maurizio_cutolo and team 👉https://t.co/6c08ucQlDN 👨‍🎓Glucocorticosteroids - a double-edged sword https://t.co/VdKlPzFpOb

Links:

@ReumatologiaJ ReumatologiaJ ( View Tweet)
Check out a NEW review on the dichotomy of #glucocorticosteroids treatment in #rheumaticdiseases by @maurizio_cutolo and team 👉https://t.co/6c08ucQlDN 👨‍🎓Glucocorticosteroids - a double-edged sword https://t.co/VdKlPzFpOb

Links:

@ReumatologiaJ ReumatologiaJ ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.